诱导受体3（DcR3）在胆管癌中的表达及意义

目的:观察胆管癌组织及血清中诱导受体3(decoy receptor 3,DcR3)蛋白的表达及其临床价值。方法:采用免疫组化S-P法检测45例胆管癌、15例癌旁胆管正常组织中DcR3蛋白的表达,ELISA法检测31例胆管癌及18例胆道良性疾病患者和28例正常人外周血清中DcR3的水平。结果:45例胆管癌组织中DcR3阳性表达29例,阳性率为64.4%,胆管正常组织中无阳性表达。DcR3的表达与肿瘤临床分期、肿瘤浸润和转移有关(P<0.05)。胆管癌患者及胆管良性疾病患者血清DcR3水平分别为152.2535.94 pg/ml,98.35 14.27 pg/ml,均高于正常人。胆管癌患者与胆道良性疾病患者血清DcR3水平相比差异有显著性(P<0.01)。结论:DcR3在胆管癌组织中表达增高。DcR3的表达与胆管癌的发生、发展以及转移有关,可成为治疗胆管癌的一个新靶点。血清DcR3的检测对胆管癌的诊断有一定的临床价值。

The expression and value of DcR3 in cholangiocarcinoma

Objective: To observe the expression of decoy receptor3(DcR3) in cholangiocarcinoma, and to investigate the value of serum concentration of DcR3 for the diagnosis of cholangiocarcinoma. Methods: The expression of DcR3 was examined by immunohistochemistry with SP staining method in 45 cases of cholangiocarcinoma, and 15 cases of bile duct normal tissue. The serum DcR3 concentration was measured using a DcR3 enzyme-linked immunosorbent assay (ELISA) in 31 cases of cholangiocarcinoma, 18 cases of bile duct benign disease while 28 healthy individuals as contrast. Results: The expression of DcR3 was detected in 29 out of the 45 cholangiocarcinoma cases with a positive rate of 64.4% , no expression of DcR3 was detected in bile duct normal tissue. The expression of DcR3 was correlated with TNM staging and lymph node metastasis (P<0.05), but not with age, tumor size, histologic grading (P>0.05). The serum DcR3 concentrations in patients with cholangiocarcinoma and in patients with bile duct benign disease is 152.25 35.94 pg/ml and 98.35 14.27 pg/ml, while the normal people is 95.01 10.03 pg/ml respectively. There was statistical difference in DcR3 concentration between cholangiocarcinoma patients and bile duct benign disease patients(P<0.01). Conclusions: The expression of DcR3 increased in cholangiocarcinoma. The expression of DcR3 is closely related to cholangiocarcinoma occurrence, progression and metastasis. DcR3 can be a new target for the therapy of cholangiocarcinoma. The serum concentration of DcR3 has clinical value for the diagnosis of Cholangiocarcinoma.